NeoGenomics with ticker code (NEO) now have 11 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 28 and 16 calculating the mean target price we have 21.45. Given that the stocks previous close was at 11.74 this indicates there is a potential upside of 82.7%. There is a 50 day moving average of 16.83 and the 200 day MA is 33.85. The market cap for the company is $1,415m. Visit the company website at: https://www.neogenomics.com
The potential market cap would be $2,585m based on the market concensus.
NeoGenomics operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
